OLMA
Olema Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.11
+8.05%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -37.8%
- EBIT
- -40.7%
- EPS
- -3.9%
- Free cash flow
- -29.5%
- Operating cash flow
- -29.5%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- -34.6%
- EPS
- -24.2%
Three-year CAGR
- Revenue
- —
- EBITDA
- -25.5%
- EBIT
- -25.6%
- Net income
- -25.5%
- EPS
- +15.0%
- Free cash flow
- -40.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026